Cancer & SURVIVEiT News
Category Filter:
Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma
Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma Naveed Saleh, MD, MS Sep 10, 2018 The United States Food and Drug Administration has announced the approval of mogamulizumab (Poteligeo) for…
Imbruvica + rituximab becomes first non-chemo combination for Waldenström’s macroglobulinemia
Imbruvica + rituximab becomes first non-chemo combination for Waldenström’s macroglobulinemia The Janssen Pharmaceutical Companies of Johnson & Johnson announced the FDA approval of Imbruvica (ibrutinib) in combination with rituximab for…
- « Previous
- 1
- 2